New inhaler propellant tested in mild asthma study
NCT ID NCT06433921
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new propellant (HFA-152a) in salbutamol inhalers works as well as the current one (HFA-134a) for people with mild asthma. 84 adults aged 18-65 will receive single doses of the inhaler or a placebo. The main goal is to measure how well the inhaler protects against airway narrowing triggered by a substance called methacholine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
salbutamol (albuterol) inhaler with a new propellant (HFA-152a)
What this could lead to
If successful, this could show that the new propellant works just as well as the current one, potentially leading to a more environmentally friendly inhaler option.
What could go wrong
This is an early phase 1 study with only 84 people, so results may not apply to everyone. The new propellant might not work as well or could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GSK Investigational Site
RECRUITINGManchester, M23 9QZ, United Kingdom
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••